ORIGAMI3 A Randomized, open label phase 3 study of Amivantamab + FOLFIRI vs Cetuximab/Bevacizumab +FOLFIRI in participants with KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable, or Metastatic Colorectal Cancer who have received prior chemotherapy



Mary Beth Wilwerding, RN Admin@NEcancertrials.com



Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*

Email*

Phone*

Message*